Member Info for Jarv55

New Dna service up and running soon
https://myhealthchecked.com/at-home-dna-testing/

Crikey Wallbrook actually tweeted https://twitter.com/WalbrookPR/status/1412690981162557440

Also they are still in discussions with other customers
Whilst customer discussions are ongoing and there is still no certainty over ongoing volumes of sales, it is likely that these increased revenue levels will continue into the summer and will have a positive impact on the results for the financial year ending 31 December 2021.

I wonder if the new testing lab will be open on Sundays
Whilst the Company's new genomic testing service has been successfully deployed to offer a COVID-19 testing service, it provides the foundation to create a wider portfolio of easy to use DNA tests over the longer-term.

The second test wasn't launched until Mid May impressive revenues
MyHealthChecked subsequently signed a second agreement with Boots to provide COVID-19 test kits and laboratory testing services for day two and day eight coronavirus testing for international arrivals, which launched mid-May.

https://twitter.com/Jarvy55/status/1412679879930306561?s=20

Would be nice if Penny did a proactive interview to back this up

We also have the dna testing about to be launched imagine selling that in Boots

EasyJet could bring in more revenue have to remember travel hasn't really got going yet.

As a result, there has been a significant uplift in sales for the period, particularly driven by higher COVID-19 testing revenues during May and June. Revenues for the six months to 30 June 2021 were £3.27m (H1 2020: £12,700), with just over £3m of these sales booked in the final two months of the period. Whilst customer discussions are ongoing and there is still no certainty over ongoing volumes of sales, it is likely that these increased revenue levels will continue into the summer and will have a positive impact on the results for the financial year ending 31 December 2021.



Cash balances at 30 June 2021 were £2.21m, reflecting investment in personnel and marketing in readiness for commercial growth, and higher than normal inventory costs during the period as stock is built up in anticipation of continued strong sales in H2 when the company expects to be cash generative (H1 2020: £1.35m).



The Company remains very optimistic about the business prospects for the full year. Post period end MyHealthChecked acquired Nell Health Ltd, a technology-led provider of genetic testing and personalised nutrition consultancy services. Nell Health's innovative technology platform offers personalised accessible and actionable outcomes to improve health and wellness based on information gathered from a Nell Health DNA test. Beyond this the acquisition also gives MyHealthChecked a fully-owned technology platform that will enable the Company to retain full ownership and IP for all of their future digital technology



Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said:

"The first half of 2021 has seen a transformation of our business ready to capitalise on the commercial opportunities before us. As I explained in our recent Full Year results, we are now a business with a highly credible, compliant and successful pharmacy customer, a high street presence, a proven service, and with an operational and commercial set-up which is now delivering growth in a regulated product, poised for the needs of the market as we enter a new period of social freedoms in 2021.



"Whilst this is an exciting opportunity, we are mindful to ensure a strong pipeline of genetic tests outside of COVID-19 to secure the firm foundations of a business backed by robust science and innovative technology that can deliver long-term sustainable revenue growth."

Key highlights

· H1 Revenues dramatically increased to £3.27m (H1 2020: £12,700) driven by COVID-19 testing services

· Cash balances of £2.21m despite investment in staffing and inventory (H1 2020: £1.35m)



One of the key features of the period was the successful acquisition and integration of The Genome Store at the end of 2020. The subsequent launch of the MyHealthChecked brand, and the launch of the ecommerce website and service, delivers on the key strategic aim of growing the Company's product portfolio into other areas of personalised health and wellness. Whilst the Company's new genomic testing service has been successfully deployed to offer a COVID-19 testing service, it provides the foundation to create a wider portfolio of easy to use DNA tests over the longer-term.



The COVID-19 testing service has been the main commercial driver of performance in the first half. MyHealthChecked's services have been included as one of the suppliers on the Government list with "Fit to Fly", "Test to Release" and "Days 2 and 8" testing, and the Company has established a key commercial partnership with Boots UK Limited ("Boots"). The MyHealthChecked COVID-19 at-home nasal swab kit and PCR laboratory testing service launched in April via www.boots.com and across over 500 Boots stores in Great Britain. MyHealthChecked subsequently signed a second agreement with Boots to provide COVID-19 test kits and laboratory testing services for day two and day eight coronavirus testing for international arrivals, which launched mid-May.

Antony Legge, Executive Chairman of RMS, said: "India represents a significant opportunity for our Pro Larva anti-viral mask and we are pleased to be partnering with Stag Global. Whilst this agreement represents an initial modest number of masks, the Company is in discussions with a number of Indian businesses regarding distribution agreements for the Pro-Lava mask and hopes to be announcing further positive news flow in the near term. This deal will help to strengthen P2F's position as a provider of anti-viral masks within the global healthcare market."

Sales Pipeline

With the manufacturing chain falling into place, P2F is now in a position to increase its sales and marketing efforts. As prices of imported generic masks that do not contain P2F's patented anti-viral layer have fallen significantly over the last year, P2F is focusing more on specific sectors where demand is less price sensitive and more concerned with the unique utility and value of P2F's ProLarva MHRA approved, anti-viral mask. The Company is pleased to announce that it has entered into a distribution agreement with Numed Holdings Limited (www.numed.co.uk), who will supply the P2F mask into GP, dental and veterinary surgeries, opticians and care homes across the UK and Ireland. Although the strong interest displayed in 2020 in P2F's anti-viral technology has yet to translate into significant sales of the ProLarva mask in 2021, P2F is currently in discussions with several potential large customers both in the UK and overseas and hopes to be able to announce some significant orders in the near future.

when did they promise a sales update I must of missed that

yes it was BS

https://uk.yahoo.com/news/chris-whitty-situations-face-mask-171755854.html

https://economictimes.indiatimes.com/news/politics-and-nation/assam-declares-complete-lockdown-in-7-districts-as-covid-19-cases-surge/videoshow/84168404.cms

https://www.bbc.co.uk/news/uk-57733276

Tha machine in Nottingham is not redundant at all it is still producing masks as well as Volz

Volz are making our masks